Additionally, no differences in OS, PFS, or DSS were noted with stratification by age ≥60 (p>0.15), double or triple expressor or high grade B cell lymphoma with Bcl-2 and Myc translocations (p>0.51), ≥3 prior lines of therapy (p>0.23), or receipt of bRT pre- or post-leukapheresis (p>0.67). This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.